Summary by Futu AI
Wuxi Bio submitted a new next-day disclosure report on September 19, 2024, disclosing changes in the issued shares or treasury shares. The report showed that Wuxi Bio issued 373,800 ordinary shares for the exercise of options at a price of HKD 4.47 per share, accounting for 0.009% of the issued shares, between September 12 and 19, 2024, according to the 2016 share plan. At the same time, the company conducted multiple share buybacks from June 11 to September 19, 2024, with a total repurchase of 34,801,000 shares at a repurchase price ranging from HKD 10.89 to HKD 11.95. All repurchased shares are intended to be cancelled. In addition, Wuxi Bio confirmed that all share issuances or treasury share sales or transfers have been formally authorized and approved by the board of directors, and comply with all applicable listing rules, laws, and other regulatory requirements. After the share buybacks, the company will enter a moratorium period until October 19, 2024, during which no new shares may be issued, and no treasury shares may be sold or transferred.
